# Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

> **NCT00856284** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 2639 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Metformin
- **DRUG:** Glipizide

## Key facts

- **NCT ID:** NCT00856284
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 2639 (ACTUAL)
- **Last updated:** 2013-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856284, "Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00856284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*